A double-blind, placebo-controlled study of memantine in the treatment of major depression - PubMed (original) (raw)
Randomized Controlled Trial
A double-blind, placebo-controlled study of memantine in the treatment of major depression
Carlos A Zarate Jr et al. Am J Psychiatry. 2006 Jan.
Abstract
Objective: This study was designed to assess possible antidepressant effects of memantine, a selective N-methyl-D-aspartate (NMDA) receptor antagonist in humans.
Method: In a double-blind, placebo-controlled study, 32 subjects with major depression were randomly assigned to receive memantine (5-20 mg/day) (N=16) or placebo (N=16) for 8 weeks. Primary efficacy was assessed by performance on the Montgomery-Asberg Depression Rating Scale (MADRS).
Results: The linear mixed models for total MADRS scores showed no treatment effect.
Conclusions: In an 8-week trial, the low-to-moderate-affinity NMDA antagonist memantine in doses of 5-20 mg/day was not effective in the treatment of major depressive disorder.
Similar articles
- A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK. Zarate CA Jr, et al. Arch Gen Psychiatry. 2006 Aug;63(8):856-64. doi: 10.1001/archpsyc.63.8.856. Arch Gen Psychiatry. 2006. PMID: 16894061 Clinical Trial. - Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial.
Smith EG, Deligiannidis KM, Ulbricht CM, Landolin CS, Patel JK, Rothschild AJ. Smith EG, et al. J Clin Psychiatry. 2013 Oct;74(10):966-73. doi: 10.4088/JCP.12m08252. J Clin Psychiatry. 2013. PMID: 24229746 Free PMC article. Clinical Trial. - The effects of add-on low-dose memantine on cytokine levels in bipolar II depression: a 12-week double-blind, randomized controlled trial.
Lee SY, Chen SL, Chang YH, Chen PS, Huang SY, Tzeng NS, Wang YS, Wang LJ, Lee IH, Wang TY, Yeh TL, Yang YK, Hong JS, Lu RB. Lee SY, et al. J Clin Psychopharmacol. 2014 Jun;34(3):337-43. doi: 10.1097/JCP.0000000000000109. J Clin Psychopharmacol. 2014. PMID: 24717258 Clinical Trial. - Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
Tariot PN. Tariot PN. J Clin Psychiatry. 2006;67 Suppl 3:15-22; quiz 23. J Clin Psychiatry. 2006. PMID: 16649847 Review. - Is Memantine Effective as an NMDA-Receptor Antagonist in Adjunctive Therapy for Schizophrenia?
Kikuchi T. Kikuchi T. Biomolecules. 2020 Jul 31;10(8):1134. doi: 10.3390/biom10081134. Biomolecules. 2020. PMID: 32751985 Free PMC article. Review.
Cited by
- Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder.
Duncan WC, Sarasso S, Ferrarelli F, Selter J, Riedner BA, Hejazi NS, Yuan P, Brutsche N, Manji HK, Tononi G, Zarate CA. Duncan WC, et al. Int J Neuropsychopharmacol. 2013 Mar;16(2):301-11. doi: 10.1017/S1461145712000545. Epub 2012 Jun 7. Int J Neuropsychopharmacol. 2013. PMID: 22676966 Free PMC article. Clinical Trial. - Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias.
Thomas SJ, Grossberg GT. Thomas SJ, et al. Clin Interv Aging. 2009;4:367-77. doi: 10.2147/cia.s6666. Epub 2009 Oct 12. Clin Interv Aging. 2009. PMID: 19851512 Free PMC article. Review. - Back to the Future of Neuropsychopharmacology.
Bespalov A, van Gaalen M, Steckler T. Bespalov A, et al. Adv Neurobiol. 2023;30:207-224. doi: 10.1007/978-3-031-21054-9_9. Adv Neurobiol. 2023. PMID: 36928852 - NMDA Receptor Activation-Dependent Antidepressant-Relevant Behavioral and Synaptic Actions of Ketamine.
Zanos P, Brown KA, Georgiou P, Yuan P, Zarate CA Jr, Thompson SM, Gould TD. Zanos P, et al. J Neurosci. 2023 Feb 8;43(6):1038-1050. doi: 10.1523/JNEUROSCI.1316-22.2022. Epub 2023 Jan 3. J Neurosci. 2023. PMID: 36596696 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources